<?xml version='1.0' encoding='utf-8'?>
<document id="26343418"><sentence text="Recent trends in preclinical drug-drug interaction studies of flavonoids--Review of case studies, issues and perspectives."><entity charOffset="62-72" id="DDI-PubMed.26343418.s1.e0" text="flavonoids" /></sentence><sentence text="Because of health benefits that are manifested across various disease areas, the consumption of herbal products and/or health supplements containing different kinds of flavonoids has been on the rise"><entity charOffset="168-178" id="DDI-PubMed.26343418.s2.e0" text="flavonoids" /></sentence><sentence text=" While the drug-drug interaction potential between flavonoids and co-ingested drugs still remain an issue, opportunities exist for the combination of flavonoids with suitable anti-cancer drugs to enhance the bioavailability of anti-cancer drugs and thereby reduce the dose size of the anti-cancer drugs and improve its therapeutic index"><entity charOffset="51-61" id="DDI-PubMed.26343418.s3.e0" text="flavonoids" /><entity charOffset="150-160" id="DDI-PubMed.26343418.s3.e1" text="flavonoids" /><pair ddi="false" e1="DDI-PubMed.26343418.s3.e0" e2="DDI-PubMed.26343418.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26343418.s3.e0" e2="DDI-PubMed.26343418.s3.e1" /></sentence><sentence text=" In recent years, scores of flavonoids have undergone preclinical investigation with variety of drugs encompassing therapeutic areas such as oncology (etoposide, doxorubicin, paclitaxel, tamoxifen etc"><entity charOffset="28-38" id="DDI-PubMed.26343418.s4.e0" text="flavonoids" /><entity charOffset="151-160" id="DDI-PubMed.26343418.s4.e1" text="etoposide" /><entity charOffset="162-173" id="DDI-PubMed.26343418.s4.e2" text="doxorubicin" /><entity charOffset="175-185" id="DDI-PubMed.26343418.s4.e3" text="paclitaxel" /><entity charOffset="187-196" id="DDI-PubMed.26343418.s4.e4" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e0" e2="DDI-PubMed.26343418.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e0" e2="DDI-PubMed.26343418.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e0" e2="DDI-PubMed.26343418.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e0" e2="DDI-PubMed.26343418.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e0" e2="DDI-PubMed.26343418.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e1" e2="DDI-PubMed.26343418.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e1" e2="DDI-PubMed.26343418.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e1" e2="DDI-PubMed.26343418.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e1" e2="DDI-PubMed.26343418.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e2" e2="DDI-PubMed.26343418.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e2" e2="DDI-PubMed.26343418.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e2" e2="DDI-PubMed.26343418.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e3" e2="DDI-PubMed.26343418.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s4.e3" e2="DDI-PubMed.26343418.s4.e4" /></sentence><sentence text="), immunosuppression (cyclosporine) and hypertension (losartan, felodipine, nitrendipine etc"><entity charOffset="22-34" id="DDI-PubMed.26343418.s5.e0" text="cyclosporine" /><entity charOffset="54-62" id="DDI-PubMed.26343418.s5.e1" text="losartan" /><entity charOffset="64-74" id="DDI-PubMed.26343418.s5.e2" text="felodipine" /><entity charOffset="76-88" id="DDI-PubMed.26343418.s5.e3" text="nitrendipine" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e0" e2="DDI-PubMed.26343418.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e0" e2="DDI-PubMed.26343418.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e0" e2="DDI-PubMed.26343418.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e0" e2="DDI-PubMed.26343418.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e1" e2="DDI-PubMed.26343418.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e1" e2="DDI-PubMed.26343418.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e1" e2="DDI-PubMed.26343418.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e2" e2="DDI-PubMed.26343418.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s5.e2" e2="DDI-PubMed.26343418.s5.e3" /></sentence><sentence text=")" /><sentence text=" The review provides examples of the recent trends in the preclinical investigation of 14 flavonoids (morin, quercetin, silibinin, kaempferol etc"><entity charOffset="90-100" id="DDI-PubMed.26343418.s7.e0" text="flavonoids" /><entity charOffset="102-107" id="DDI-PubMed.26343418.s7.e1" text="morin" /><entity charOffset="109-118" id="DDI-PubMed.26343418.s7.e2" text="quercetin" /><entity charOffset="120-129" id="DDI-PubMed.26343418.s7.e3" text="silibinin" /><entity charOffset="131-141" id="DDI-PubMed.26343418.s7.e4" text="kaempferol" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e0" e2="DDI-PubMed.26343418.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e0" e2="DDI-PubMed.26343418.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e0" e2="DDI-PubMed.26343418.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e0" e2="DDI-PubMed.26343418.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e0" e2="DDI-PubMed.26343418.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e1" e2="DDI-PubMed.26343418.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e1" e2="DDI-PubMed.26343418.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e1" e2="DDI-PubMed.26343418.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e1" e2="DDI-PubMed.26343418.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e2" e2="DDI-PubMed.26343418.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e2" e2="DDI-PubMed.26343418.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e2" e2="DDI-PubMed.26343418.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e3" e2="DDI-PubMed.26343418.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26343418.s7.e3" e2="DDI-PubMed.26343418.s7.e4" /></sentence><sentence text=") with various co-administered drugs" /><sentence text=" The relevance of combination of flavonoids with anti-cancer drugs and a framework to help design the in vitro and in vivo preclinical studies to gain better mechanistic insights are discussed"><entity charOffset="33-43" id="DDI-PubMed.26343418.s9.e0" text="flavonoids" /></sentence><sentence text=" Also, concise discussions on the various physiological factors that contribute for the reduced bioavailability of flavonoids along with the significant challenges in the data interpretation are provided"><entity charOffset="115-125" id="DDI-PubMed.26343418.s10.e0" text="flavonoids" /></sentence><sentence text="" /></document>